KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

MT Newswires Live12-18 23:54

KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the added convenience of oral dosing in a phase 3 study, BofA Securities said in a note on Wednesday.

The firm assigned a 75% likelihood of success for the drug in the US market and projects that risk-adjusted peak sales of $604 million by 2035 will contribute $19 per share to KalVista's valuation.

Despite a competitive acute hereditary angioedema market, sebetralstat's oral dosing offers significant differentiation, potentially driving broad adoption as injectable therapies can be cumbersome and delay treatment, according to the note.

BofA said that the launch of Biocryst Pharmaceuticals' (BCRX) Orladeyo demonstrates a strong precedent for market success as it achieved a significant share in a crowded hereditary angioedema market due to its oral dosing advantage.

The firm initiated coverage of KalVista with a buy rating and a price objective of $22.

Price: 8.69, Change: +0.04, Percent Change: +0.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492395138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 23:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492395138","market":"us","top_or_hot":-1,"title":"KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says","media":"MT Newswires Live","content":"<html><body><p> KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the added convenience of oral dosing in a phase 3 study, BofA Securities said in a note on Wednesday.</p><p>The firm assigned a 75% likelihood of success for the drug in the US market and projects that risk-adjusted peak sales of $604 million by 2035 will contribute $19 per share to KalVista's valuation.</p><p>Despite a competitive acute hereditary angioedema market, sebetralstat's oral dosing offers significant differentiation, potentially driving broad adoption as injectable therapies can be cumbersome and delay treatment, according to the note.</p><p>BofA said that the launch of Biocryst Pharmaceuticals' (BCRX) Orladeyo demonstrates a strong precedent for market success as it achieved a significant share in a crowded hereditary angioedema market due to its oral dosing advantage.</p><p>The firm initiated coverage of KalVista with a buy rating and a price objective of $22.</p><p>Price: 8.69, Change: +0.04, Percent Change: +0.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 23:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169589451.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492395138","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492395138","pubTimestamp":1734537289,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"KalVista Pharmaceuticals'  drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the added convenience of oral dosing in a phase 3 study, BofA Securities said in a note on Wednesday.The firm assigned a 75% likelihood of success for the drug in the US market and projects that risk-adjusted peak sales of $604 million by 2035 will contribute $19 per share to KalVista's valuation.Despite a competitive acute hereditary angioedema market, sebetralstat's oral dosing offers significant differentiation, potentially driving broad adoption as injectable therapies can be cumbersome and delay treatment, according to the note.BofA said that the launch of Biocryst Pharmaceuticals'  Orladeyo demonstrates a strong precedent for market success as it achieved a significant share in a crowded hereditary angioedema market due to its oral dosing advantage.The firm initiated coverage of KalVista with a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","BK4139":"生物科技","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","BK4198":"医疗保健用品","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","BK4547":"WSB热门概念","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","HAE":"美国血液技术","KALV":"Kalvista Pharmaceuticals Inc","BCRX":"BioCryst制药","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV"},"translate_title":"美国银行表示，KalVista Pharmaceuticals的Sebetralstat有望凭借口服优势颠覆急性HAE市场","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1,"BCRX":0.9,"KALV":0.9},"content_text":"KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the added convenience of oral dosing in a phase 3 study, BofA Securities said in a note on Wednesday.The firm assigned a 75% likelihood of success for the drug in the US market and projects that risk-adjusted peak sales of $604 million by 2035 will contribute $19 per share to KalVista's valuation.Despite a competitive acute hereditary angioedema market, sebetralstat's oral dosing offers significant differentiation, potentially driving broad adoption as injectable therapies can be cumbersome and delay treatment, according to the note.BofA said that the launch of Biocryst Pharmaceuticals' (BCRX) Orladeyo demonstrates a strong precedent for market success as it achieved a significant share in a crowded hereditary angioedema market due to its oral dosing advantage.The firm initiated coverage of KalVista with a buy rating and a price objective of $22.Price: 8.69, Change: +0.04, Percent Change: +0.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492395138"}